Industry

Aims to combine NETRIS Pharma’s mAb with selected radioisotopes LYON, France–(BUSINESS WIRE)–NETRIS Pharma SAS, a private clinical-stage biopharmaceutical company, announced today that it has entered into a scientific collaboration agreement with Orano and the Centre Léon Bérard (CLB) to develop novel Antibody Radio-Conjugates for the treatment of cancer. Initially, the parties intend to conduct a … [Read more…]

GOSSELIES, Belgium & MONT-SAINT-GUIBERT, Belgium–(BUSINESS WIRE)–Cellistic, the cell therapy development and manufacturing business of Ncardia BV, and Celyad Oncology (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced today a transaction whereby Cellistic will acquire Celyad Oncology’s Good … [Read more…]

Over two thirds of customers are interested in physical and financial wellness, yet only 8% of insurers have established the necessary capabilities. PARIS–(BUSINESS WIRE)–Capgemini and Qorus’ inaugural World Life and Health Insurance Report, published today, reveals that customers consider insurers among the top two preferred providers1 for physical and financial wellness advice. However, most insurers … [Read more…]

Study of the Paradise™ Ultrasound Renal Denervation System Shows significant Reduction in Blood Pressure in Patients with Uncontrolled Hypertension TOKYO–(BUSINESS WIRE)–Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) a wholly owned subsidiary of Otsuka Holdings today announced the detailed results from the RADIANCE II US FDA IDE pivotal trial evaluating the endovascular Paradise™ Ultrasound Renal … [Read more…]

ATLANTA–(BUSINESS WIRE)–$VIRI #Biotech–Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today the pricing of its underwritten public offering of 10.0 million shares of its common stock at a public offering price of $0.50 per share, for gross proceeds of … [Read more…]

NEW YORK–(BUSINESS WIRE)–Ahead of the Seventh Replenishment of the Global Fund to Fight AIDS, Tuberculosis and Malaria in New York City on Sept. 21, AIDS Healthcare Foundation (AHF) announced that it will pledge $10 million to the Fund – the world’s best financing mechanism for fighting infectious diseases. “Given the Global Fund’s outstanding track record … [Read more…]

BRUKINSA Is the First Bruton’s Tyrosine Kinase (BTK) Inhibitor Recommended by NICE for Routine Use for WM BRUKINSA Is the Only BTK Inhibitor Considered Cost Effective in WM CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING–(BUSINESS WIRE)–BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company that is developing and commercializing oncology medicines, today announced … [Read more…]

Evidence-based clinical guidance will aid practitioners treating patients with monkeypox LOS ANGELES–(BUSINESS WIRE)–#bestinklass—Zynx Health today announced that it has published new order set and care plan guidelines to aid clinicians in the treatment of patients diagnosed with monkeypox. Created by the Zynx Clinical Team and based on recommendations from World Health Organization and the Centers … [Read more…]

ATLANTA–(BUSINESS WIRE)–$VIRI #Biotech–Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today that it intends to offer to sell shares of its common stock in an underwritten public offering. All of the shares of common stock are to be sold … [Read more…]

CAMBRIDGE, England, & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that an article highlighting preclinical data from BT8009, a Nectin-4 targeting Bicycle Toxin Conjugate, was published in Molecular Cancer Therapeutics. The article, titled “BT8009: a Nectin-4 … [Read more…]